Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Radiation Oncology
Would you recommend hypofractionated treatment for early stage, bilateral breast cancers?
Assume each primary meets ASTRO 2018 guidelines
Answer from: Radiation Oncologist at Community Practice
yes as i don't see any reason and have done multiple times
Sign in or Register to read more
Answer from: Radiation Oncologist at Academic Institution
Agreed, key is to ensure fields are set up to prevent any potential overlap
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
Yes, check for overlap. Otherwise, there is no glaring contraindication.
Sign in or Register to read more
4383
4395
4397
Related Questions
For path CR after neoadjuvant chemotherapy in breast cancer with sentinel node (2-3 nodes) negative but >4 nodes positive on initial PET, do you boost the nodes not assessed by sentinel node?
Would you start any treatment for radiation pneumonitis if there is a large area of consolidation in the irradiated lung field but the patient is asymptomatic?
How would you approach a cT4 cN2 (22 cm in size) TNBC that shrank to 9 cm with KN-522 regimen but remains inoperable at the end of treatment?
Would you offer ultrahypofractionated 5 fraction breast radiation to a patient with lupus?
What rates of breast (not arm) lymphedema would you quote to patients post-lumpectomy and adjuvant radiation?
Do you offer ultra-hypofractionated 5-fraction whole breast RT after oncoplastic rearrangement?
How would you manage a post-menopausal patient who has simple mastectomy for DCIS, but was found to have invasive ductal carcinoma on post-operative pathology?
When doing a tumor bed boost following whole breast irradiation, what do you typically use for CTV and PTV margin for photon and electron plans?
In what clinical scenario, if any, would you consider APBI appropriate treatment for a patient with triple-negative breast cancer?
How does residual DCIS after neoadjuvant chemotherapy impact prognosis if there is a CR of the invasive disease?